Potentiation of Glucose Uptake in 3T3-L1 Adipocytes by PPARγ Agonists Is Maintained in Cells Expressing a PPARγ Dominant-Negative Mutant: Evidence for Selectivity in the Downstream Responses to PPARγ Activation
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Pharmacological agonists for the nuclear receptor PPAR gamma enhance glucose disposal in a variety of insulin-resistant states in humans and animals. The precise mechanisms whereby activation of PPAR gamma leads to increased glucose uptake in metabolically active cells remain to be determined. Notably, certain novel, synthetic PPAR gamma ligands appear to antagonize thiazolidinedione-induced adipogenesis yet stimulate cellular glucose uptake. We have explored the molecular mechanisms underlying the enhancement of glucose uptake produced by PPAR gamma agonists in 3T3-L1 adipocytes. Rosiglitazone treatment for 48 h significantly increased basal and insulin-stimulated glucose uptake and markedly increased the cellular expression of GLUT1 but not GLUT4. Rosiglitazone increased plasma membrane levels of GLUT1, but not GLUT4, both basally and after insulin stimulation. Surprisingly, adenoviral expression of a dominant-negative mutant PPAR gamma, which was demonstrated to strongly inhibit adipogenesis, completely failed to inhibit rosiglitazone-stimulated glucose uptake. Similar findings were obtained with the non-thiazolidinedione PPAR gamma agonists, GW1929 and GW7845. The insensitivity of PPAR gamma agonist-stimulated glucose uptake to expression of a dominant-negative mutant, compared with the latter's marked inhibitory effects on preadipocyte differentiation, suggests that, as is the case for other nuclear receptors, the precise molecular mechanisms linking PPAR gamma activation to downstream events may differ depending on the nature of the biological response. The growing evidence that the effects of PPAR gamma on adipogenesis and glucose uptake can be dissociated may have important implications for the development of improved antidiabetic drug treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“Thus, TZDs have effects on suppression of the adipocytederived signaling molecules, TNF and leptin, and on FFA partitioning between adipose and muscle tissues ( 29 , 30), all of which may secondarily improve whole organism insulin sensitivity.”
BackgroundBarroso, I., Gurnell, M., Crowley, V. E. F., Agostini, M., Schwabe, J. W., Soos, M. A., Maslen, G. L., Williams, T. D. M., Lewis, H., Schafer, A. J., et al. (1999) · Nature · doi:10.1038/47254 · Cited by 1,368
Self-citationBerger, J., Bailey, P., Biswas, C., Cullinan, C. A., Doebber, T. W., Hayes, N. S., Saperstein, R., Smith, R. G., & Leibowitz, M. D. (1996) · Endocrinology · doi:10.1210/endo.137.10.8828476 · Cited by 391
Cited by
Jones, J. R., Barrick, C., Kim, K.-A., Lindner, J., Blondeau, B., Fujimoto, Y., Shiota, M., Kesterson, R. A., Kahn, B. B., & Magnuson, M. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306743102 · Cited by 486
Wilson-Fritch, L., Burkart, A., Bell, G., Mendelson, K., Leszyk, J., Nicoloro, S., Czech, M., & Corvera, S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.3.1085-1094.2003 · Cited by 459
Pharmacological Inhibition of Glucosylceramide Synthase Enhances Insulin Sensitivity
Aerts, J. M., Ottenhoff, R., Powlson, A. S., Grefhorst, A., van Eijk, M., Dubbelhuis, P. F., Aten, J., Kuipers, F., Serlie, M. J., Wennekes, T., et al. (2007) · Diabetes · doi:10.2337/db06-1619 · Cited by 301
Self-citationKnouff, C., & Auwerx, J. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0036 · Cited by 256
Powelka, A. M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26040 · Cited by 236
Metadata
- Authors
- Nugent, C., Prins, J. B., Whitehead, J. P., Savage, D., Wentworth, J. M., Chatterjee, V. K., & O’Rahilly, S.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2001-10
- Volume
- 15
- Issue
- 10
- Pages
- 1729-1738
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2046731226
- Cited by
- 92
- References
- 3
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potentiation of Glucose Uptake in 3T3-L1 Adipocytes by PPARγ Agonists Is Maintained in Cells Expressing a PPARγ Dominant-Negative Mutant: Evidence for Selectivity in the Downstream Responses to PPARγ Activation. https://app.cochat.ai/papers/10.1210/mend.15.10.0715
- The paper
- Nugent, C., Prins, J. B., Whitehead, J. P., Savage, D., Wentworth, J. M., Chatterjee, V. K., & O’Rahilly, S. (2001). Potentiation of Glucose Uptake in 3T3-L1 Adipocytes by PPARγ Agonists Is Maintained in Cells Expressing a PPARγ Dominant-Negative Mutant: Evidence for Selectivity in the Downstream Responses to PPARγ Activation. Molecular Endocrinology. https://doi.org/10.1210/mend.15.10.0715
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.